Concord Biotech Future Growth
Future criteria checks 5/6
Concord Biotech is forecast to grow earnings and revenue by 22.9% and 18.4% per annum respectively. EPS is expected to grow by 23.4% per annum. Return on equity is forecast to be 26.1% in 3 years.
Key information
22.9%
Earnings growth rate
23.4%
EPS growth rate
Pharmaceuticals earnings growth | 17.9% |
Revenue growth rate | 18.4% |
Future return on equity | 26.1% |
Analyst coverage | Low |
Last updated | 05 Jul 2024 |
Recent future growth updates
No updates
Earnings and Revenue Growth Forecasts
Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
---|---|---|---|---|---|
3/31/2027 | 18,289 | 6,294 | 4,670 | 6,009 | 3 |
3/31/2026 | 15,192 | 5,003 | 3,223 | 4,125 | 4 |
3/31/2025 | 12,453 | 3,913 | 2,655 | 3,309 | 4 |
3/31/2024 | 10,169 | 3,081 | 1,798 | 2,655 | N/A |
12/31/2023 | 9,706 | 3,046 | N/A | N/A | N/A |
9/30/2023 | 9,704 | 3,044 | 1,589 | 2,665 | N/A |
6/30/2023 | 8,670 | 2,453 | N/A | N/A | N/A |
3/31/2023 | 8,532 | 2,401 | 1,009 | 2,460 | N/A |
3/31/2022 | 7,129 | 1,749 | 526 | 2,081 | N/A |
3/31/2021 | 6,169 | 2,349 | -374 | 1,668 | N/A |
3/31/2020 | 5,123 | 1,691 | -6 | 1,548 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: CONCORDBIO's forecast earnings growth (22.9% per year) is above the savings rate (6.7%).
Earnings vs Market: CONCORDBIO's earnings (22.9% per year) are forecast to grow faster than the Indian market (16.3% per year).
High Growth Earnings: CONCORDBIO's earnings are expected to grow significantly over the next 3 years.
Revenue vs Market: CONCORDBIO's revenue (18.4% per year) is forecast to grow faster than the Indian market (9.7% per year).
High Growth Revenue: CONCORDBIO's revenue (18.4% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: CONCORDBIO's Return on Equity is forecast to be high in 3 years time (26.1%)